Reframing Obesity Webinar 3: Managing Concerns and Improving Adherence (April 22, 2025)-Managing Concerns and Improving Adherence

Video Transcription

Video Summary

In the Reframing Obesity Treatment Series session titled “Optimizing Care, Managing Concerns, and Improving Adherence," moderated by Maria Mogollon, experts including Dr. Jennifer Clemens, Dr. Jaime Almondos, and Dr. Monisha Chadha discussed obesity pharmacotherapy, focusing on side effects, adherence, and patient-centered strategies.<br /><br />Dr. Clemens led the case-based discussion which included interactive polling questions to engage participants on real-world scenarios. The cases highlighted challenges in obesity treatment, such as managing gastrointestinal side effects and losing muscle mass with GLP-1 receptor agonist therapy. The faculty advised on initial patient education, adjustment in dose escalation, and strategies to maximize protein intake and engage in resistance training to mitigate muscle loss.<br /><br />Safety concerns, like the risk of thyroid C-cell tumors and pancreatitis, were considered, with emphasis on patient education and close monitoring. Discussion included newer evidence for managing gallbladder disease risk and discontinuation guidelines for major surgical procedures.<br /><br />To tackle adherence and access issues, strategies for overcoming insurance barriers, such as submitting prior authorization requests, were shared. A survey from 2012 was mentioned, revealing patient willingness to pay based on anticipated weight loss and treatment convenience, illustrating evolving patient expectations and cost-related challenges.<br /><br />The session concluded with answers to audience questions on using GLP-1 in patients with prior pancreatitis and engaging specific populations such as those with ulcerative colitis. This comprehensive discussion highlighted the importance of individualized care, shared decision-making, and continuous patient-provider communication in obesity management.

Keywords

obesity treatment

pharmacotherapy

side effects

patient adherence

GLP-1 receptor agonist

patient education

insurance barriers

individualized care

shared decision-making

patient-provider communication